Management

Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters. - Dr Reddy"s to strengthen domestic biz - Dr Reddy"s plans to launch Lipitor"s generic version in US - Dr Reddy"s develops generic version of Pfizer"s Lipitor - Intermediate trend reversal confirmed - DRL net doubles to Rs 217 cr - Dr Reddy"s forays into transdermal patch segment The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of Nordic Bioscience said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Declare Ambani MoU illegal, govt asks SC
It treats KG gas as personal property of the brothers, says SLP.
Popular Articles
payday loan lenders

Analysts' View: Raamdeo Agrawal
The finance minister (FM) has done a good job to maintain an aggregate demand in a recessionary situation by increasing rural spending and giving some reprieve in income tax by cutting the surcharge. It’s a fairly balanced Budget. The fall in markets is an over-reaction as the finance minister has never said that there would not be any divestment. Instead, he has hinted that nearly Rs 25,000 crore is likely to be raised through divestment.

FMCG 'dream choice' for fresh MBA graduates
The Fast Moving Consumer Goods (FMCG) sector has emerged as the industry of choice for this year’s management graduates.

© Copyright 2009